August 01, 2014 9:50 PM ET

Biotechnology

Company Overview of Creabilis SA

Company Overview

Creabilis SA, a clinical stage biotechnology company, engages in the research and development of new drugs for the treatment of dermatology and inflammatory diseases. Its development stage product portfolio includes CT327, a TrkA kinase inhibitor for the treatment of psoriasis and atopic dermatitis; CT340, a TrkA kinase and MAP2K3 kinase inhibitor for the treatment of inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for the treatment of inflammatory conditions, such as lupus, acute liver failure, and fibrosis. The company is also involved in various early stage projects for the development of candidates for dermatological and other indications. Creabilis SA was founded in 2003...

5, Rue JeanMonnet

Luxembourg,  2180

Luxembourg

Founded in 2003

Phone:

352 26 420 522

Key Executives for Creabilis SA

Chief Executive Officer and Director
Head of Finance and Operations and Vice President
Head of Development and Senior Vice President
Chief Medical officer
Senior Vice President for Chemistry Manufacturing and Controls
Compensation as of Fiscal Year 2014.

Creabilis SA Key Developments

Creabilis SA Appoints Gil Yosipovitch and Praveen Anand to its Scientific Advisory Board

Creabilis SA announced that it has appointed Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board. Gil Yosipovitch is the newly announced Chair of the Department of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine, and is one of the renowned experts in pruritus. Praveen Anand is Professor of Clinical Neurology and Head of the Centre for Clinical Translation at Hammersmith Hospital, Imperial College London, UK.

Creabilis Announces Encouraging Results from Phase IIb Psoriasis Trial

Creabilis has announced results from the company's Phase IIb trial with CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology that creates 'topical-by-design' drugs. Patients receiving CT327 showed a statistically significant and clinically meaningful reduction in pruritus compared to blinded placebo vehicle. Pruritus was measured using a visual analogue scale (VAS), the accepted regulatory endpoint. The reduction from baseline in pruritus VAS reached 60% for CT327 compared to 20% for vehicle alone (p<0.05). A clinically meaningful reduction in pruritus (VAS greater than or equal to 20mm) was seen in up to 79% of patients for CT327 compared to 36% for vehicle alone (p<0.05). At baseline, 69% of patients reported at least moderate pruritus (VAS > 40mm). An improvement was also seen in the CT327 treated groups versus vehicle in mPASI (modified Psoriasis Area and Severity Index) in all patients. In patients with at least moderate pruritus at the start of the trial, significant reductions in mPASI were observed for CT327 compared to vehicle. There was no significant impact of any dose of CT327 on the IGA (Investigator Global Assessment) endpoint. CT327 was safe and well tolerated with no site application reactions and no systemic exposure. Notably, patients on CT327 reported fewer adverse events and withdrawals due to pruritus than the vehicle treated patients.

Creabilis SA Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327

Creabilis SA announced headline results of its phase 2b trial with its lead product, CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology that creates 'topical-by-design' drugs. Chronic pruritus is a debilitating symptom of many dermatological diseases and has a significant impact on quality of life, including sleep. It is the cardinal symptom in atopic dermatitis and a key symptom of psoriasis. No medicine is currently approved for chronic pruritus. Patients receiving CT327 showed a statistically significant and clinically meaningful reduction in pruritus compared to blinded placebo vehicle. Pruritus was measured using a visual analogue scale (VAS), the accepted regulatory endpoint. The reduction from baseline in pruritus VAS reached 60% for CT327 compared to 20% for vehicle alone (p<0.05). A clinically meaningful reduction in pruritus (VAS >= 20mm) was seen in up to 79% of patients for CT327 compared to 36% for vehicle alone (p<0.05). At baseline, 69% of patients reported at least moderate pruritus (VAS > 40mm). An improvement was also seen in the CT327 treated groups versus vehicle in mPASI (modified Psoriasis Area and Severity Index) in all patients. In patients with at least moderate pruritus at the start of the trial, significant reductions in mPASI were observed for CT327 compared to vehicle. There was no significant impact of any dose of CT327 on the IGA (Investigator Global Assessment) endpoint. CT327 was safe and well tolerated with no site application reactions and no systemic exposure. Notably, patients on CT327 reported fewer adverse events and withdrawals due to pruritus than the vehicle treated patients.

Similar Private Companies By Industry

Company Name Region
Creabilis SA Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Creabilis SA, please visit www.creabilis-sa.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.